Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Files An 8-K Other Events
Item8.01.
| Other Events. |
On April 20, 2017, Atara Biotherapeutics, Inc. issued a press
release titled Atara Bio Announces Positive Interim Results from
Ongoing Phase 1 Trial of the Autologous Version of ATA188 in
Patients with Primary and Secondary Progressive Multiple
Sclerosis (MS) at the American Academy of Neurology (AAN) Annual
Meeting 2017, a copy of which is attached hereto as Exhibit 99.1
and is incorporated by reference herein.
| Item9.01. | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit Number |
Description |
|
| 99.1 | Press Release, dated April20, 2017. |
About Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Recent Trading Information
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) closed its last trading session up +0.45 at 18.90 with 196,539 shares trading hands.
